Cited by 1,008T-cell and B-cell ImmunologyCancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

The DOI matches its Crossref record; 41 of the 44 references it cites were found in a registry or an index.

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Open access

Sutmuller, Roger P.M., van Duivenvoorde, Leonie M., van Elsas, Andrea, Schumacher, Ton N.M., Wildenberg, Manon E., Allison, James P., Toes, Rene E.M., Offringa, Rienk, Melief, Cornelis J.M.·2001·The Journal of Experimental Medicine

DOI 10.1084/jem.194.6.823PMC PMC2195955

Open this paper in CoChat — free account

Abstract

Therapeutic efficacy of a tumor cell–based vaccine against experimental B16 melanoma requires the disruption of either of two immunoregulatory mechanisms that control autoreactive T cell responses: the cytotoxic T lymphocyte–associated antigen (CTLA)-4 pathway or the CD25+ regulatory T (Treg) cells. Combination of CTLA-4 blockade and depletion of CD25+ Treg cells results in maximal tumor rejection. Efficacy of the antitumor therapy correlates with the extent of autoimmune skin depigmentation as well as with the frequency of tyrosinase-related protein 2180–188–specific CTLs detected in the periphery. Furthermore, tumor rejection is dependent on the CD8+ T cell subset. Our data demonstrate that the CTL response against melanoma antigens is an important component of the therapeutic antitumor response and that the reactivity of these CTLs can be augmented through interference with immunoregulatory mechanisms. The synergism in the effects of CTLA-4 blockade and depletion of CD25+ Treg cells indicates that CD25+ Treg cells and CTLA-4 signaling represent two alternative pathways for suppression of autoreactive T cell immunity. Simultaneous intervention with both regulatory mechanisms is therefore a promising concept for the induction of therapeutic antitumor immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1084/jem.194.6.823

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Signaling by intrathymic cytokines, not T cell antigen receptors, specifies CD8 lineage choice and promotes the differentiation of cytotoxic-lineage T cells
Park, J., Adoro, S., Guinter, T. I., Erman, B., Alag, A., Catálfamo, M., Kimura, M. Y., Cui, Y., Lucas, P. J., Gress, R. E., et al. (2010) · Nature Immunology · doi:10.1038/ni.1840 · Cited by 5,835
Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases
Sakaguchi, S., Sakaguchi, N., Asano, M., Itoh, M., & Toda, M. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.155.3.1151 · Cited by 5,608
Phenotypic Analysis of Antigen-Specific T Lymphocytes
Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., & Davis, M. M. (1996) · Science · doi:10.1126/science.274.5284.94 · Cited by 3,544 · cited 1×
“H-2K b tetramers were produced as described previously (20, 21) and stored frozen in Tris-buffered saline/16% glycerol/0.”
Method
CD4+CD25+ Immunoregulatory T Cells Suppress Polyclonal T Cell Activation In Vitro by Inhibiting Interleukin 2 Production
Thornton, A. M., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.2.287 · Cited by 2,637
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 2×
“Anderson Cancer Center, Houston, TX), GM-CSF‐producing B16 cell lines BL6/GM-E, BL6/GM18 (18), B16/B7.1 (18), 9H10 ( 19 ), and PC61 (American Type Culture Collection) were cultured in Iscove’s IMDM (BioWhittaker) supplemented with 1 U/ml penicillin, 1 � g/ml streptomycin, 2 � M L -glutamine, 20 � M � -mercaptoethanol…”
MethodSelf-citation
Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Cytotoxic T Lymphocyte–Associated Antigen 4 Plays an Essential Role in the Function of Cd25+Cd4+ Regulatory Cells That Control Intestinal Inflammation
Read, S., Malmström, V., & Powrie, F. M. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.295 · Cited by 2,206
B7/CD28 Costimulation Is Essential for the Homeostasis of the CD4+CD25+ Immunoregulatory T Cells that Control Autoimmune Diabetes
Salomon, B. L., Lenschow, D. J., Rhee, L., Ashourian, N., Singh, B., Sharpe, A. H., & Bluestone, J. A. (2000) · Immunity · doi:10.1016/s1074-7613(00)80195-8 · Cited by 2,058
Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state.
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,566

Flagged first, then by citations

Show all 44 references

3 of the 44 references couldn’t be matched to a known paper.

Sorted by citations

Items 401–500 of 1,000

Suppression of anti-cancer immunity by regulatory T cells: Back to the future
Orentas, R. J., Kohler, M. E., & Johnson, B. D. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.007 · Cited by 64
Immune suppression by tumor-specific CD4+ regulatory T-cells in cancer
Wang, R. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.009 · Cited by 64
Making room for T cells
Maine, G. N., & Mulé, J. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16166 · Cited by 64
Role of Foxp3-positive Tumor-infiltrating Lymphocytes in the Histologic Features and Clinical Outcomes of Hepatocellular Carcinoma
Mathai, A. M., Kapadia, M. J., Alexander, J., Kernochan, L. E., Swanson, P. E., & Yeh, M. M. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31824e9b7c · Cited by 63
Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer
Drescher, K. M., Sharma, P., Watson, P. A., Gatalica, Z., Thibodeau, S. N., & Lynch, H. T. (2009) · Familial Cancer · doi:10.1007/s10689-009-9233-0 · Cited by 63
Immunotherapy opportunities in ovarian cancer
Chu, C., Kim, S. H., June, C. H., & Coukos, G. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.2.243 · Cited by 63
Antitumor activity mediated by double-negative T cells.
Young, K. J., Kay, L. S., Phillips, M. J., & Zhang, L. (2003) · PubMed · Cited by 63
Targeted killing of TNFR2-expressing tumor cells and Tregs by TNFR2 antagonistic antibodies in advanced Sézary syndrome
Torrey, H., Khodadoust, M. S., Tran, L., Baum, D., DEFUSCO, A. A., Kim, Y. H., & Faustman, D. L. (2018) · Leukemia · doi:10.1038/s41375-018-0292-9 · Cited by 63
Mechanisms of Tumor Evasion
Campoli, M. R., Ferrone, S., Zea, A. H., Rodrı́guez, P. C., & Ochoa, A. C. (2007) · Springer eBooks · doi:10.1007/0-387-27545-2_3 · Cited by 63
Breaking tolerance in cancer immunotherapy: time to ACT
Overwijk, W. W. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.01.011 · Cited by 63
Graft-versus-Leukemia and Graft-versus-Host Reactions after Donor Lymphocyte Infusion Are Initiated by Host-Type Antigen-Presenting Cells and Regulated by Regulatory T Cells in Early and Long-Term Chimeras
Xia, G., Truitt, R. L., & Johnson, B. D. (2006) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2005.11.519 · Cited by 63
Platelets and Regulatory T Cells May Induce a Type 2 Immunity That Is Conducive to the Progression and Fibrogenesis of Endometriosis
Xiao, F., Liu, X., & Guo, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.610963 · Cited by 62
Peripheral T-Cell Tolerance Associated with Prostate Cancer Is Independent from CD4+CD25+ Regulatory T Cells
Degl'Innocenti, E., Grioni, M., Capuano, G., Jachetti, E., Freschi, M., Bertilaccio, M. T. S., Michelini, R. H., Doglioni, C., & Bellone, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2429 · Cited by 64
Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors.
Mulryan, K., Ryan, M. G., Myers, K. A., Shaw, D. M., WANG, W. W., Kingsman, S. M., Stern, P. L., & Carroll, M. W. (2002) · PubMed · Cited by 61
Distinct Effects of IL-18 on the Engraftment and Function of Human Effector CD8+ T Cells and Regulatory T Cells
Carroll, R. G., Carpenito, C., Shan, X., Danet-Desnoyers, G. A., Liu, R., Jiang, S., Albelda, S. Μ., Golovina, T. N., Coukos, G., Riley, J. L., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003289 · Cited by 60
Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma
Guo, J., Zhu, J., Sheng, X., Wang, X., Qu, L., Yan, H., Liu, Y., Zhang, H., Huo, L., Zhang, S., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22551 · Cited by 60
Balancing between Antitumor Efficacy and Autoimmune Pathology in T-Cell–Mediated Targeting of Carcinoembryonic Antigen
Bos, R., van Duikeren, S., Morreau, H. M., Franken, K. L. M. C., Schumacher, T. N., Haanen, J. B. A. G., van der Burg, S. H., Melief, C. J. M., & Offringa, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1864 · Cited by 60
Self-citation
Immunometabolism in biofilm infection: lessons from cancer
Mirzaei, R., Sabokroo, N., Ahmadyousefi, Y., Motamedi, H., & Karampoor, S. (2022) · Molecular Medicine · doi:10.1186/s10020-022-00435-2 · Cited by 60
Dendritic cell-based vaccines in cancer immunotherapy: an update on clinical and immunological results
Lesterhuis, W. J., de Vries, I. J. M., Adema, G. J., & Punt, C. J. A. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh919 · Cited by 60
Better understanding tumor–host interaction in head and neck cancer to improve the design and development of immunotherapeutic strategies
Badoual, C., Sandoval, F., Péré, H., Hans, S., Gey, A., Merillon, N., Ryswick, C. V., Quintin‐Colonna, F., Bruneval, P., Brasnu, D. F., et al. (2010) · Head & Neck · doi:10.1002/hed.21346 · Cited by 61
Toward the Discovery of Vaccine Adjuvants: Coupling In Silico Screening and In Vitro Analysis of Antagonist Binding to Human and Mouse CCR4 Receptors
Davies, M. N., Bayry, J., Tchilian, E. Z., Vani, J., Shaila, M. S., Forbes, E. K., Draper, S. J., Beverley, P. C. L., Tough, D. F., & Flower, D. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008084 · Cited by 59
Inability to Mediate Prolonged Reduction of Regulatory T Cells After Transfer of Autologous CD25-depleted PBMC and Interleukin-2 After Lymphodepleting Chemotherapy
Powell, D. J., de Vries, C. R., Allen, T., Ahmadzadeh, M., & Rosenberg, S. A. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3180600ff9 · Cited by 59
Immunotherapeutic Potential of B7-DC (PD-L2) Cross-Linking Antibody In Conferring Antitumor Immunity
Radhakrishnan, S., Nguyen, L. T., Ćirić, B., Flies, D. B., Keulen, V. P. V., Tamada, K., Chen, L., Rodriguez, M., & Pease, L. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3025 · Cited by 59
Retracted
Basic Science Review: Nitric Oxide—Releasing Prosthetic Materials
Varu, V. N., Tsihlis, N. D., & Kibbe, M. R. (2008) · Vascular and Endovascular Surgery · doi:10.1177/1538574408322752 · Cited by 59
BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals
Bodman‐Smith, M. D. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg204 · Cited by 58
IL-4 Modulation of CD4+CD25+ T Regulatory Cell-Mediated Suppression
Pace, L., Pioli, C., & Doria, G. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7645 · Cited by 57
Regulating the immune response to tumours
Betts, G. J., Clarke, S. L., Richards, H. E., Godkin, A. J., & Gallimore, A. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.05.006 · Cited by 56
Skin Melanoma Development in ret Transgenic Mice Despite the Depletion of CD25+Foxp3+ Regulatory T Cells in Lymphoid Organs
Kimpfler, S., Sevko, A., Ring, S., Falk, C. S., Osen, W., Frank, K., Kato, M., Mahnke, K., Schadendorf, D., & Umansky, V. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900609 · Cited by 58
Regulatory T Cells Suppress Natural Killer Cell Immunity in Patients With Human Cervical Carcinoma
Chang, W., Li, C.-H., Chu, L.-H., Huang, P.-S., Sheu, B., & Huang, S. (2015) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000578 · Cited by 56
Unraveling the Complex Relationship Between Cancer Immunity and Autoimmunity: Lessons from Melanoma and Vitiligo
Uchi, H., Stan, R., Turk, M. J., Engelhorn, M. E., Rizzuto, G. A., Goldberg, S. M., Wolchok, J. D., & Houghton, A. N. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90006-6 · Cited by 56
Regulatory T cells and Toll-like receptors in tumor immunity
Wang, R., Peng, G., & Wang, H. Y. (2006) · Seminars in Immunology · doi:10.1016/j.smim.2006.01.008 · Cited by 56
Dendritic cells transduced with TAT protein transduction domain‐containing tyrosinase‐related protein 2 vaccinate against murine melanoma
Shibagaki, N., & Udey, M. C. (2003) · European Journal of Immunology · doi:10.1002/eji.200323709 · Cited by 57
Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model
Sorensen, M. R., Holst, P. J., Steffensen, M. A., Christensen, J. P., & Thomsen, A. R. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.07.066 · Cited by 55
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers
Ragupathi, G., Koide, F., Sathyan, N., Kagan, E., Spassova, M. K., Bornmann, W. G., Gregor, P. D., Reis, C. A., Clausen, H., Danishefsky, S. J., et al. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0399-2 · Cited by 55
CD154 on the surface of CD4+CD25+ regulatory t cells contributes to skin transplant tolerance
Jarvinen, L. Z., Blazar, B. R., Adeyi, O. A., Strom, T. B., & Noelle, R. J. (2003) · Transplantation · doi:10.1097/01.tp.0000093462.16309.73 · Cited by 55
Enhancing cancer vaccines with immunomodulators
Berinstein, N. L. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.06.043 · Cited by 55
The role and mechanisms of double negative regulatory T cells in the suppression of immune responses.
Chen, W., Ford, M. S., Young, K. J., & Zhang, L. (2004) · PubMed · Cited by 55
Regulatory T cells expressing abundant CTLA‐4 on the cell surface with a proliferative gene profile are key features of human head and neck cancer
Matoba, T., Imai, M., Ohkura, N., Kawakita, D., Ijichi, K., Toyama, T., Morita, A., Murakami, S., Sakaguchi, S., & Yamazaki, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.32024 · Cited by 54
Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination
Nishikawa, H., Qian, F., Tsuji, T., Ritter, G., Old, L. J., Gnjatic, S., & Odunsi, K. O. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.6340 · Cited by 54
Immune checkpoint inhibitors for the treatment of melanoma
Sabbatino, F., Liguori, L., Pepe, S., & Ferrone, S. (2022) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2022.2038132 · Cited by 56
Treatment of transplanted CT26 tumour with dendritic cell vaccine in combination with blockade of vascular endothelial growth factor receptor 2 and CTLA-4
Pedersen, A. E., Buus, S., & Claësson, M. H. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.04.012 · Cited by 53
Roadmap to a Better Therapeutic Tumor Vaccine
Emens, L. A. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992423 · Cited by 53
Effector/Memory but Not Naive Regulatory T Cells Are Responsible for the Loss of Concomitant Tumor Immunity
Lin, Y., Chang, L.-Y., Huang, C., Peng, H., Dutta, A., Chen, T., Yeh, C., & Lin, C. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803829 · Cited by 56
Immune checkpoint blockade: Releasing the brake towards hematological malignancies
Xia, Y., Medeiros, L. J., & Young, K. H. (2015) · Blood Reviews · doi:10.1016/j.blre.2015.11.003 · Cited by 53
Effect of CD4+CD25+ and CD4+CD25− T Regulatory Cells on the Generation of Cytolytic T Cell Response to a Self but Human Tumor-Associated Epitope In Vitro
Chattopadhyay, S., Mehrotra, S., Chhabra, A., Hegde, U. P., Mukherji, B., & Chakraborty, N. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.2.984 · Cited by 53
Therapy of established B16-F10 melanoma tumors by a single vaccination of CTL/T helper peptides in VacciMax®
Mansour, M., Pohajdak, B., Kast, W. M., Fuentes-Ortega, A., Korets-Smith, E., Weir, G. M., Brown, R. G., & Daftarian, P. M. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-20 · Cited by 52
Making room for T cells
Maine, G. N., & Mulé, J. J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216166 · Cited by 52
An anti-CTLA-4 heavy chain–only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile
Gan, X., Shan, Q., Li, H., Janssens, R., Shen, Y., He, Y., Chen, F., van Haperen, R., Drabek, D., Li, J., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2200879119 · Cited by 51
Anti-CTLA4 antibody clinical trials in melanoma
Ribas, A. (2007) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2007.09.001 · Cited by 51
Association of Cytotoxic T Lymphocyte-associated antigen-4 gene haplotype with the susceptibility to gastric cancer
Hou, R., Cao, B., Zhong-dong, C., Li, Y., Ning, T., Xu, C., Xu, C., & Chen, Z. (2009) · Molecular Biology Reports · doi:10.1007/s11033-009-9705-1 · Cited by 51
Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells
Chuang, C.-M., Hoory, T., Monie, A., Wu, A. A., Wang, M., & Hung, C. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.11.042 · Cited by 51
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some
Rowdo, F. P. M., Barón, A., Urrutia, M., & Mordoh, J. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00127 · Cited by 51
Regulatory T-cells have a prominent role in the immune modulated vaccine response by specific oligosaccharides
Land, B. V., Schijf, M. A., van Esch, B. C. A. M., van Bergenhenegouwen, J., Bastiaans, J., Schouten, B., Boon, L., & Garssen, J. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.06.046 · Cited by 51
Tumor Microenvironment as a New Target for Tumor Immunotherapy of Polysaccharides
Liu, L., Nie, S., & Xie, J. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2015.1077191 · Cited by 51
Hyperfunction of CD4 CD25 regulatory T cells in de novo acute myeloid leukemia
Wan, Y., Zhang, C., Xu, Y., Wang, M., Rao, Q., Xing, H., Tian, Z., Tang, K., Mi, Y., Wang, Y., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-06961-8 · Cited by 51
Regulatory T cells and innate immune regulation in tumor immunity
Wang, R. (2006) · Springer Seminars in Immunopathology · doi:10.1007/s00281-006-0022-7 · Cited by 51
Type 1 and type 2 tumor infiltrating effector cell subpopulations in progressive breast cancer
Reome, J. B., Hylind, J. C., Dutton, R. W., & Dobrzanski, M. J. (2004) · Clinical Immunology · doi:10.1016/j.clim.2003.11.013 · Cited by 52
Immunoregulatory T cells in cancer immunotherapy
Morse, M. A., Clay, T. M., Mosca, P. J., & Lyerly, H. K. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.8.827 · Cited by 51
Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer
Arens, R., van Hall, T., van der Burg, S. H., OSSENDORP, F. A., & Melief, C. J. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.04.008 · Cited by 52
Self-citation
Anti‐tumor activity of an anti‐endoglin monoclonal antibody is enhanced in immunocompetent mice
Tsujie, M., Tsujie, T., Toi, H., Uneda, S., SHIOZAKI, K., Tsai, H., & Seon, B. K. (2008) · International Journal of Cancer · doi:10.1002/ijc.23314 · Cited by 50
Targeting the Immunoregulator SRA/CD204 Potentiates Specific Dendritic Cell Vaccine-Induced T-cell Response and Antitumor Immunity
Yi, H., Guo, C., Yu, X., Gao, P., Qian, J., Zuo, D., Manjili, M. H., Fisher, P. B., Subjeck, J. R., & Wang, X. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1801 · Cited by 50
Tumor blood vessels, a difficult hurdle for infiltrating leukocytes
Castermans, K., & Griffioen, A. W. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2007.07.005 · Cited by 50
Arginine methylation of FOXP3 is crucial for the suppressive function of regulatory T cells
Kagoya, Y., Saijo, H., Matsunaga, Y., Guo, T., Saso, K., Anczurowski, M., Wang, C.-H., Sugata, K., Murata, K., Butler, M. O., et al. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.09.011 · Cited by 50
T-Cell Regulatory Mechanisms in Specific Immunotherapy
Jutel, M., & Akdiş, C. A. (2008) · Chemical immunology/Fortschritte der Allergielehre/Progress in allergy/Chemical immunology and allergy · doi:10.1159/000155000 · Cited by 50
Regulatory T Cells, a Potent Immunoregulatory Target for CAM Researchers: Modulating Tumor Immunity, Autoimmunity and Alloreactive Immunity (III)
Vojdani, A., & Erde, J. (2006) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nel047 · Cited by 53
Prognostic value of peripheral and local forkhead box P3+ regulatory T cells in patients with non-small-cell lung cancer
Hasegawa, T., Suzuki, H., Yamaura, T., Muto, S., Okabe, N., Osugi, J., Hoshino, M., Higuchi, M., Ise, K., & Gotoh, M. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.299 · Cited by 49
Regulatory T-cell directed therapies in liver diseases
Oo, Y. H., & Sakaguchi, S. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.05.034 · Cited by 49
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy
Hong, M. M. Y., & Vareki, S. M. (2022) · Cancers · doi:10.3390/cancers14061580 · Cited by 52
Dendritic cells: tools and targets for antitumor vaccination
den Brok, M. H., Nierkens, S., Figdor, C. G., Ruers, T. J. M., & Adema, G. J. (2005) · Expert Review of Vaccines · doi:10.1586/14760584.4.5.699 · Cited by 52
Co‐stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily
Peggs, K. S., & Allison, J. P. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05627.x · Cited by 51
Self-citation
Practical Aspects of Poultry Vaccination
Schijns, V. E. C. J., van de Zande, S., Lupiani, B., & Reddy, S. M. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-396965-1.00020-0 · Cited by 48
T lymphocyte dependence of the antibody response to ‘T lymphocyte independent type 2’ antigens
Jeurissen, A., Ceuppens, J. L., & Bossuyt, X. (2003) · Immunology · doi:10.1111/j.1365-2567.2004.01775.x · Cited by 48
Immune-related biomarkers for diagnosis/prognosis and therapy monitoring of cutaneous melanoma
Neagu, M. T., Constantin, C., & Tănase, C. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.81 · Cited by 48
Regulatory T cells increase in breast cancer and in stage IV breast cancer
Wang, Z.-K., Yang, B. Y., Liu, H., Hu, Y., Yang, J., Wu, L., Zhou, Z., & Jiao, S. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1158-4 · Cited by 47
Advances of MUC1 as a target for breast cancer immunotherapy.
Yang, E., Hu, X. F., & Xing, P. (2007) · PubMed · doi:10.14670/hh-22.905 · Cited by 47
Roles of CD4+CD25high FOXP3+ Tregs in lymphomas and tumors are complex
Ke, X., Wang, J., Li, L., Chen, I.-L., Wang, H., & Yang, X. (2008) · Frontiers in bioscience · doi:10.2741/2986 · Cited by 47
The Role of the CTLA4 Blockade in the Treatment of Malignant Melanoma
Cranmer, L. D., & Hersh, E. M. (2007) · Cancer Investigation · doi:10.1080/07357900701522315 · Cited by 47
Clinical implications of antigen transfer mechanisms from malignant to dendritic cells
Arina, A., Tirapu, I., Alfaro, C., Rodrı́guez-Calvillo, M., Mazzolini, G. D., Inogés, S., López, A., Feijoó, E., Bendandi, M., & Melero, I. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(02)00956-6 · Cited by 48
CD36 and Its Role in Regulating the Tumor Microenvironment
Liao, X., Yan, S., Li, J., Jiang, C., Huang, S., Liu, S., Zou, X., Zhang, G., Zou, J., & Liu, Q. (2022) · Current Oncology · doi:10.3390/curroncol29110642 · Cited by 47
The Roles of CD4+T Cells in Tumor Immunity
Lai, Y., Jeng, C., & Chen, S.-C. (2011) · ISRN Immunology · doi:10.5402/2011/497397 · Cited by 47
CD27-Mediated Regulatory T Cell Depletion and Effector T Cell Costimulation Both Contribute to Antitumor Efficacy
Wasiuk, A., Testa, J. S., Weidlick, J., Sisson, C., Vitale, L. A., Widger, J., Crocker, A., Thomas, L. J., Goldstein, J., Marsh, H. C., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700606 · Cited by 47
Mechanisms of Allergen-Specific Immunotherapy: T-Regulatory Cells and More
Verhagen, J., Blaser, K., Akdiş, C. A., & Akdis, M. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.02.008 · Cited by 46
Immunological and Clinical Effects of Vaccines Targeting p53‐Overexpressing Malignancies
Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J. M., Daemen, T., & Nijman, H. W. (2011) · BioMed Research International · doi:10.1155/2011/702146 · Cited by 46
Self-citation
Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★
Hueman, M. T., Stojadinovic, A., Storrer, C. E., Foley, R. J., Gurney, J. M., Shriver, C. D., Ponniah, S., & Peoples, G. E. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9108-5 · Cited by 46
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases
Lee, C., Kakinuma, T., Wang, J., Zhang, H., Palmer, D. C., Restifo, N. P., & Hwang, S. T. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0310 · Cited by 46
Increased regulatory T‐cell frequencies in patients with advanced melanoma correlate with a generally impaired T‐cell responsiveness and are restored after dendritic cell‐based vaccination
Correll, A., Tuettenberg, A., Becker, C., & Jonuleit, H. (2010) · Experimental Dermatology · doi:10.1111/j.1600-0625.2009.01055.x · Cited by 45
RNA Vaccines in Cancer Treatment
Bringmann, A., Held, S. A. E., Heine, A., & Brossart, P. (2010) · BioMed Research International · doi:10.1155/2010/623687 · Cited by 45
An Enhanced Heterologous Virus-Like Particle for Human Papillomavirus Type 16 Tumour Immunotherapy
Jemon, K. B., Young, V. L., Wilson, M., McKee, S. J., Ward, V. K., Baird, M. A., Young, S. L., & Hibma, M. H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0066866 · Cited by 44
Modification of the tumor microenvironment to enhance immunity
Liao, Y. (2007) · Frontiers in bioscience · doi:10.2741/2336 · Cited by 44
Cancer vaccine strategies: translation from mice to human clinical trials
Berzofsky, J. A., Terabe, M., Trepel, J. B., Pastan, I. H., Stroncek, D. F., Morris, J. C., & Wood, L. V. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2084-x · Cited by 44
Functional control of regulatory T cells and cancer immunotherapy
Wang, R. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.11.004 · Cited by 44
Immunotherapy in multiple myeloma – possibility or probability?
Harrison, S. J., & Cook, G. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05534.x · Cited by 42
The Indispensable Role of CCR5 for In Vivo Suppressor Function of Tumor-Derived CD103+ Effector/Memory Regulatory T Cells
Chang, L.-Y., Lin, Y., Kang, C.-W., Hsu, C.-Y., Chu, Y., Huang, C., Day, Y., Chen, T., Yeh, C., & Lin, C. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200266 · Cited by 43
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
Xue, W., Metheringham, R. L., Brentville, V. A., Gunn, B., Symonds, P., Yagita∥, H., Ramage, J. M., & Durrant, L. G. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1169353 · Cited by 43
Transient Treg depletion enhances therapeutic anti‐cancer vaccination
Fisher, S. A., Aston, W. J., Chee, J., Khong, A., Cleaver, A. L., Solin, J. N., Ma, S., Lesterhuis, W. J., Dick, I. M., Holt, R. A., et al. (2016) · Immunity Inflammation and Disease · doi:10.1002/iid3.136 · Cited by 46
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma
Wang, X., Zuo, D., Sarkar, D., & Fisher, P. B. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.629187 · Cited by 44
Reverse immunology approach for the identification of CD8 T‐cell‐defined antigens: Advantages and hurdles
Viatte, S., Alves, P. M. S., & Romero, P. J. (2006) · Immunology and Cell Biology · doi:10.1111/j.1440-1711.2006.01447.x · Cited by 46
Depletion of CD25+ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma
Jing, W., Yan, X., Hallett, W. H. D., Gershan, J. A., & Johnson, B. D. (2011) · Blood · doi:10.1182/blood-2010-12-326108 · Cited by 42
Antigen choice in adoptive T-cell therapy of cancer
Offringa, R. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.02.006 · Cited by 42
Self-citation
Identification and Epitope Enhancement of a PAX-FKHR Fusion Protein Breakpoint Epitope in Alveolar Rhabdomyosarcoma Cells Created by a Tumorigenic Chromosomal Translocation Inducing CTL Capable of Lysing Human Tumors
van den Broeke, L. T., Pendleton, C. D., Mackall, C. L., Helman, L. J., & Berzofsky, J. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2549 · Cited by 42

Authors: Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M.
Affiliations: Leiden University Medical Center (NL)
aDepartment of Immunohematology and Blood Transfusion, Tumor Immunology Lab, E3-Q, Leiden University Medical Center, 2300 RC Leiden, Netherlands
The Netherlands Cancer Institute (NL)
University of California, Berkeley (US)
ORCID: Schumacher, Ton N.M.
Wildenberg, Manon E.
Allison, James P.
Offringa, Rienk
Melief, Cornelis J.M.
Venue: The Journal of Experimental Medicine
Publisher: Rockefeller University Press
Published: 2001-09-17
Volume: 194
Issue: 6
Pages: 823-832
ISSN: 0022-1007 (ISSN-L)
1540-9538
DOI: 10.1084/jem.194.6.823
PMC: PMC2195955
OpenAlex: W2148911309
Cited by: 1,008
References: 44
Citations by year: 2026: 3 · 2025: 7 · 2024: 8 · 2023: 12 · 2022: 15 · 2021: 15 · 2020: 18 · 2019: 11 · 2018: 12 · 2017: 25 · 2016: 22 · 2015: 36 · 2014: 26 · 2013: 48 · 2012: 41
FWCI: 13.30
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: cc-by-nc-sa
Locations: The Journal of Experimental Medicine (publishedVersion)
PubMed Central (publishedVersion, cc-by-nc-sa)
PubMed (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Topics: Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CTLA-4 blockade, CD25+ regulatory T cells, Treg depletion, antitumor immunity, B16 melanoma, CD8+ T cells, tyrosinase-related protein 2, immune regulation, tumor rejection
MeSH terms: Abatacept, Animals, Antibodies, Monoclonal, Antigens, Differentiation, Antigens, Neoplasm, Female, Immunotherapy, Lymphocyte Depletion, Melanoma, Experimental, Mice, Inbred C57BL, Mice, Nude, T-Lymphocytes, Cytotoxic, Tumor Cells, Cultured, Receptors, Interleukin-2, Biomarkers, CD4-Positive T-Lymphocytes, Antigens, CD, Immunoconjugates, Intramolecular Oxidoreductases, Mice, CTLA-4 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks